Fate Therapeutics (FATE) EBT Margin (2012 - 2026)
Fate Therapeutics' (FATE) quarterly EBT Margin came in at 11371.52% in Q1 2026, down 106599.0% YoY from N/an in Q1 2025, and down 378.99% on a QoQ basis from 2374.07% in Q4 2025.
Fate Therapeutics (FATE) EBT Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of EBT Margin data on file, last reported at 11371.52% in Q1 2026.
- Quarterly EBT Margin fell 106599.0% year-over-year to 11371.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4757.39% (up 261898.0% YoY) and the FY2025 annual result came in at 7894.25%, down 382201.0% from the prior year.
- EBT Margin eased to 11371.52% in Q1 2026, from 2374.07% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 154.22% in Q1 2023 to a low of 22578.39% in Q4 2024.
- A 5-year average of 6942.4% and a median of 4324.7% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 2112792 bps — and 2025, when it jumped 2020432 bps.
- Tracing FATE's EBT Margin over 5 years: stood at 806.62% in 2022, then sank by 2619 bps to 21934.55% in 2023, then decreased by 3 bps to 22578.39% in 2024, then surged by 89 bps to 2374.07% in 2025, then tumbled by 379 bps to 11371.52% in 2026.
- The last three EBT Margin figures came in at 11371.52% (Q1 2026), 2374.07% (Q4 2025), and 4324.7% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -11,371.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,371.52% |
| Dec 31, 2025 | -2,374.07% |
| Sep 30, 2025 | -4,324.70% |
| Jun 30, 2025 | -2,358.00% |
| Mar 31, 2025 | -10,305.52% |
| Dec 31, 2024 | -22,578.39% |
| Sep 30, 2024 | -6,502.90% |
| Jun 30, 2024 | -2,892.88% |
| Mar 31, 2024 | -5,410.08% |
| Dec 31, 2023 | -21,934.55% |
| Sep 30, 2023 | -10,963.17% |
| Jun 30, 2023 | -13,075.67% |
| Mar 31, 2023 | -154.22% |
| Dec 31, 2022 | -806.62% |
| Sep 30, 2022 | -1,036.51% |
| Jun 30, 2022 | -1,443.03% |
| Mar 31, 2022 | -489.06% |
| Dec 31, 2021 | -1,733.46% |
| Sep 30, 2021 | -1,700.53% |
| Jun 30, 2021 | -948.84% |